Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 2173631Generated: November 1, 2026

2-(Chloromethyl)-5-methyl-1,3,4-oxadiazole → 5-tert-Butyl-3-(5-methyl-[1,3,4]oxadiazol-2-ylmethyl)-7-(2-oxa-6-aza-spiro[3.3]hept-6-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine

https://huagongshe.com/reaction/2173631

Reaction equation

Participants

RoleNameHCIDCharge
Reactant2-(Chloromethyl)-5-methyl-1,3,4-oxadiazoleHCID 3826620—
Reactant5-tert-Butyl-7-(3,3-difluoro-pyrrolidin-1-yl)-3-ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidineHCID 71558205—
ReactantHCID 178441781HCID 178441781—
Product5-tert-Butyl-3-(5-methyl-[1,3,4]oxadiazol-2-ylmethyl)-7-(2-oxa-6-aza-spiro[3.3]hept-6-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidineHCID 86683358—

Reaction Steps

In analogy to the procedure described for the synthesis of 5-tert-butyl-7-(3,3-difluoropyrrolidin-1-yl)-3-ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-Butyl-7-(2-oxa-6-aza-spiro[3.3]hept-6-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine and 2-(chloromethyl)-5-methyl-1,3,4-oxadiazole and isolated as white solid. MS(m/e): 371.2 (MH+).

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS09056866B2
Source datasetuspto-grants-2015_06
ORD IDord-28c0af8cf1c24e579a9e4e285278872b
Source noteuspto-grants-2015_06